XML 15 R7.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash flows from operating activities:    
Net Income (Loss) $ (56,609) $ (46,038)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation and amortization 18,931 14,605
Share-based compensation expense 115,714 92,337
Non-cash operating lease expense 6,432 6,323
Net amortization of premium or discount on investments (4,197) (5,134)
Losses (gains) on foreign exchange (677) 360
Changes in operating assets and liabilities, net of effects of business combination:    
Accounts receivable (13,922) (15,782)
Prepaid expenses and other assets (2,973) (6,923)
Deferred contract acquisition costs (6,661) (8,150)
Accounts payable 6,712 (1,669)
Accrued expenses and other liabilities 4,301 7,958
Operating lease liabilities (6,550) (6,207)
Deferred revenue 34,533 30,126
Net cash provided by operating activities 95,034 61,806
Cash flows from investing activities:    
Purchases of short-term investments (443,217) (379,546)
Maturities of short-term investments 349,080 340,889
Sales of short-term investments 0 98,178
Purchases of property and equipment (2,620) (2,509)
Payments for business combination, net of cash acquired 0 (156,714)
Net cash used in investing activities (96,757) (99,702)
Cash flows from financing activities:    
Proceeds from exercise of share options 9,971 8,804
Proceeds from employee share purchase plan 11,917 8,744
Proceeds from employee equity transactions, net of payments to tax authorities 7,300 (724)
Net cash provided by financing activities 29,188 16,824
Effect of exchange rate changes on cash, cash equivalents and restricted cash 1,021 (700)
Net increase (decrease) in cash, cash equivalents, and restricted cash 28,486 (21,772)
Cash, cash equivalents, and restricted cash—beginning of period 50,627 84,777
Cash, cash equivalents, and restricted cash—end of period 79,113 63,005
Supplemental disclosures of noncash investing and financing activities:    
Fair value of ordinary shares issued as consideration for business acquisition 0 13,420
Fair value of replacement awards in business acquisition $ 0 $ 375